Related by context. Frequent words. (Click for all words.) 73 blind randomized controlled 69 placebo controlled randomized 69 blind randomized 67 Phase III randomized 67 blind randomized placebo 60 randomized Phase III 60 blinded placebo controlled 60 multicentre 59 randomized placebo controlled 59 nab paclitaxel 59 prospective randomized controlled 59 active comparator 58 multicenter randomized 58 randomized #:# 58 placebo controlled 58 Pivotal Phase 57 multicenter randomized double 57 prospective randomized 57 Phase 1a 57 placebo controlled clinical 57 relapsed refractory multiple myeloma 56 Pivotal Trial 56 TRITON TIMI 56 randomized controlled 56 Pivotal Phase III 56 registrational trial 56 phase IIa 56 ascending doses 56 pivotal Phase III 56 Multicenter 56 multicenter clinical 56 label multicenter 55 phase IIb 55 double blinded placebo 55 blind placebo controlled 55 multicenter 55 prospective observational 55 dose escalation trial 54 label dose escalation 54 axitinib 54 Thrombolysis 54 Phase Ib clinical 54 confirmatory Phase III 54 randomized controlled clinical 54 Phase III Clinical Trial 54 Phase 1b clinical 54 plus dexamethasone 53 PRECiSE 53 Phase IIa trial 53 dacarbazine 53 Phase III pivotal 53 irbesartan 53 dose regimens 53 dose cohorts 53 deforolimus 53 Phase 2b trial 53 Phase III 53 Amrubicin 53 Phase 2b clinical 52 Randomized 52 superficial bladder cancer 52 pertuzumab 52 Phase Ib 52 placebo controlled trials 52 RESOLUTE 52 Phase III clinical 52 Taxotere R 52 peginterferon alfa 2b 52 metastatic hormone refractory 52 Taxotere ® 52 Acute Myocardial Infarction 52 Phase III Trial 52 Phase 2b 52 Phase 1b 52 Phase 1b trial 52 Completes Enrollment 52 plus gemcitabine 52 diabetic neuropathic pain 52 plus prednisone 52 Phase 2b study 52 substudy 52 administered subcutaneously 51 Navelbine 51 FOLFIRI 51 Rosuvastatin 51 registrational 51 mg BID 51 single ascending dose 51 NCT# 51 Phase Ia 51 Laquinimod 51 Pegasys R 51 tolvaptan 51 azacitidine 51 #mg dose [003] 51 subgroup analyzes 51 dose escalation study 51 Monotherapy 50 PROPEL trial 50 Phase IIb trial 50 PRECISE